Welcome to our dedicated page for Nektar Therapeutics news (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Nektar Therapeutics (Nasdaq: NKTR) generates a steady flow of news tied to its role as a clinical-stage biotechnology company focused on autoimmune and chronic inflammatory diseases. Company announcements emphasize progress with its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), a regulatory T cell stimulator and IL-2 pathway agonist being evaluated in multiple mid-stage trials.
News coverage frequently highlights clinical data from the REZOLVE-AD Phase 2b study in moderate-to-severe atopic dermatitis and the REZOLVE-AA Phase 2b study in severe-to-very-severe alopecia areata. Press releases describe topline results, detailed efficacy and safety outcomes, and analyses in subgroups such as patients with atopic dermatitis and a history of asthma, including Asthma Control Questionnaire (ACQ-5) findings.
Investors and observers can also find updates on regulatory interactions, such as the U.S. Food and Drug Administration granting Fast Track designations for rezpegaldesleukin in atopic dermatitis and alopecia areata. Additional news items cover Nektar’s participation in scientific and investor conferences, late-breaking oral presentations at major dermatology and allergy meetings, and corporate events like equity offerings and compliance updates related to its Nasdaq Capital Market listing.
This news page aggregates these disclosures so readers can follow developments in Nektar’s immunology pipeline, including rezpegaldesleukin and other programs such as NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255. For those tracking NKTR stock or the evolution of Treg-focused therapies, this feed provides a centralized view of clinical milestones, financial communications and key corporate announcements.
Nektar (Nasdaq: NKTR) will announce fourth-quarter and year-ended December 31, 2025 financial results on Thursday, March 12, 2026 after U.S. market close. Howard Robin, president and CEO, will host a conference call at 5:00 p.m. ET / 2:00 p.m. PT.
A live audio-only webcast and the press release will be available on the company’s Investors page. The webcast replay is available through April 12, 2026. Attendees must pre-register to receive dial-in details and a PIN for the live call.
Nektar Therapeutics (Nasdaq: NKTR) announced management will participate in two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference in Boston (March 2-4) and Jefferies Biotech on the Beach Summit in Miami (March 9-11).
The TD Cowen presentation is webcast on Wednesday, March 4, 2026 at 9:10 a.m. ET with a replay available for 30 days; one-on-one meetings at Jefferies are available by request.
Nektar Therapeutics (Nasdaq: NKTR) announced a research collaboration with UCSF and Dr. Stephen L. Hauser to study NKTR-0165, a first-in-class TNFR2 agonist antibody, in multiple sclerosis models. UCSF will conduct and fund the research; Nektar will supply NKTR-0165 and retain program rights.
The work will test TNFR2 agonism for neuroprotection, reduced neurodegeneration, and cell repair in neuron exposures to patient-derived B cells.
Nektar Therapeutics (Nasdaq: NKTR) closed an underwritten public offering that generated approximately $460 million in gross proceeds on Feb 13, 2026. The company sold 7,637,931 shares (including 1,034,482 shares from full exercise of the underwriters' option) and 293,103 pre-funded warrants.
Shares were priced at $58.00 per share and pre-funded warrants at $57.9999, before underwriting discounts, commissions and offering expenses. Jefferies, TD Cowen and Piper Sandler led the deal.
Nektar Therapeutics (Nasdaq: NKTR) priced an upsized public offering to raise approximately $400 million by selling 6,603,449 common shares and 293,103 pre-funded warrants at $58.00 (or $57.9999 for warrants) per unit.
The offering may close on February 13, 2026, includes a 30-day underwriter option for up to 1,034,482 additional shares, and intends net proceeds for general corporate purposes, including Phase 3 rezpegaldesleukin development and manufacturing.
Nektar Therapeutics (Nasdaq: NKTR) on Feb. 10, 2026 announced a proposed underwritten public offering of $300,000,000 of common stock and, for certain investors, pre-funded warrants, with a 30-day option for up to an additional $45,000,000. The offering is subject to market conditions.
Proceeds are intended for general corporate purposes, including research and development, clinical development (including Phase 3 trials for rezpegaldesleukin), and manufacturing. Jefferies, TD Cowen, and Piper Sandler are joint bookrunning managers. The securities will be offered under a Form S-3ASR shelf registration that became effective Nov. 12, 2025.
Nektar Therapeutics (Nasdaq: NKTR) reported 36-week blinded maintenance results from the 52-week REZOLVE-AD Phase 2b study of rezpegaldesleukin in moderate-to-severe atopic dermatitis.
Key findings: durable EASI-75/EASI-90 and vIGA-AD 0/1 maintenance with 24 µg/kg Q4W and Q12W, up to 5-fold increases in EASI-100 during maintenance, favorable safety with 3.5% discontinuation for adverse events, and plan to advance to Phase 3 with a target BLA submission in 2029.
Nektar (Nasdaq: NKTR) will host an investor call and live webcast on February 10, 2026 at 8:00 am ET to review topline results from the 36‑week maintenance period of the Phase 2b REZOLVE-AD study of rezpegaldesleukin in moderate-to-severe atopic dermatitis.
According to the company, a morning press release will publish the results, slides will be posted on the Nektar investor events page, and a replay will be available for at least 30 days.
Nektar Therapeutics (NASDAQ: NKTR) announced that on January 21, 2026 its Organization and Compensation Committee granted non-qualified stock options to purchase 1,600 shares to one newly hired employee under the 2025 Inducement Plan.
The options have an exercise price of $36.92 (closing price on January 21, 2026), an eight-year term, and vest over four years (25% after one year, then monthly 1/48ths).
Nektar Therapeutics (Nasdaq: NKTR) reported topline 36-week results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin in 92 patients with severe-to-very-severe alopecia areata. Both dose arms showed mean SALT score reductions of 28.2% (24 µg/kg) and 30.3% (18 µg/kg) versus 11.2% for placebo; the primary endpoint narrowly missed statistical significance in the mITT population. Excluding four patients with major eligibility violations, the primary endpoint reached significance (29.6% and 30.4% vs 5.7%, p=0.049 and p=0.042). Key secondary outcomes (SALT30, SALT≤30/20/10) favored treatment. Safety was described as well tolerated with mostly mild-to-moderate TEAEs and a 1.4% discontinuation rate in treatment arms. Nektar plans to advance rezpegaldesleukin to Phase 3 in 2026 and will present additional data in 2026.